10-Q: FibroGen Faces Going Concern Doubt Amid China Sale

FibroGen reports reduced losses and significant cost cuts, but warns of substantial doubt about its ability to continue as a going concern without the pending $210 million China asset sale.

Summary

• FibroGen reported a net loss of $7.6 million for Q2 2025, a significant improvement from $15.5 million in Q2 2024.
• Loss from continuing operations for Q2 2025 was $13.7 million, down from $47.1 million in Q2 2024, primarily due to substantial reductions in operating costs and expenses.
• Total revenue for continuing operations increased to $1.3 million in Q2 2025 from $1.0 million in Q2 2024, driven by drug product revenue.
• For the six months ended June 30, 2025, net cash provided by operating activities was $15.4 million, a significant improvement from a $99.2 million use of cash in the prior year period, largely due to the distribution of a litigation settlement and collections from Falikang.
• The company entered into an agreement on February 20, 2025, to sell all of its roxadustat assets in China (FibroGen International) to AstraZeneca Treasury Limited for an aggregate purchase price of approximately $210 million, expected to close in Q3 2025.
• FibroGen has retained roxadustat rights in the U.S., Canada, and Mexico, and is pursuing development for anemia in lower-risk Myelodysplastic Syndromes (MDS), with a positive FDA Type-C meeting in July 2025.
• The company is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) for metastatic castration-resistant prostate cancer (mCRPC), with a Phase 2 study anticipated to start in Q3 2025.
• A 1-for-25 reverse stock split was effected on June 16, 2025.
• The company has identified substantial doubt about its ability to continue as a going concern within 12 months if the China sale does not close, or if it cannot access additional cash from China operations or raise U.S. capital.
• A $1.25 million civil penalty settlement was reached with the SEC in May 2025, subject to Commission approval, related to roxadustat's cardiovascular safety data.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the explicit 'going concern' warning, significant revenue decline in continuing operations, and the high dependency on the China asset sale for liquidity. While cost reductions are positive, they are reactive to financial distress. The pipeline progress is promising but still carries substantial development and commercialization risk, overshadowed by immediate financial uncertainties.

Positives

• Net loss significantly improved to $7.6 million in Q2 2025 from $15.5 million in Q2 2024, and to $3.0 million for the six months ended June 30, 2025, from $48.5 million in the prior year.
• Operating costs and expenses decreased substantially by 72% in Q2 2025 and 75% for the six months ended June 30, 2025, primarily due to a 75% reduction in U.S. workforce and termination of pamrevlumab programs.
• Net cash provided by operating activities was $15.4 million for the six months ended June 30, 2025, a significant turnaround from a $99.2 million use of cash in the same period last year, driven by litigation settlement distribution and collections from China operations.
• The pending sale of China assets to AstraZeneca for approximately $210 million is expected to provide a significant cash infusion, with $96.5 million in cash and cash equivalents and $22.1 million in accounts receivable from China already classified as held for sale.
• Positive Type-C meeting with the FDA in July 2025 for roxadustat in lower-risk MDS, aligning on Phase 3 study design, indicating progress in a high-value indication.
• Encouraging preliminary median radiographic progression-free survival (rPFS) of 10.2 months observed in a Phase 1b/2 study of FG-3246 in combination with enzalutamide for mCRPC.
• FG-3246 Phase 1 study showed a 20% confirmed objective response rate and 80% disease control rate in heavily-pretreated mCRPC patients, with a median duration of response of 7.5 months.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern within 12 months without the closing of the China asset sale or additional capital raises.
• Cash and cash equivalents for continuing operations decreased to $23.4 million at June 30, 2025, from $50.5 million at December 31, 2024, indicating ongoing cash burn in the core business.
• Total revenue for the six months ended June 30, 2025, significantly decreased by 84% to $4.1 million from $26.4 million in the prior year, primarily due to the termination of the AstraZeneca U.S./RoW Agreement.
• Income from discontinued operations (China assets) significantly decreased to $6.1 million in Q2 2025 from $31.6 million in Q2 2024, and to $27.5 million for the six months ended June 30, 2025, from $47.7 million in the prior year.
• Roxadustat's inclusion in China's 11th round of volume-based purchasing program is expected to lead to further price reductions and significantly impact market access and topline revenue from China.
• The senior secured term loan facilities of $73.7 million are now classified as current liabilities, maturing on May 8, 2026, and the company must maintain a minimum of $18.75 million unrestricted cash in the U.S. to avoid default.
• The company incurred a $1.25 million civil penalty as part of an SEC settlement related to roxadustat's cardiovascular safety data.

Risks

• Substantial dependence on the success of roxadustat and FG-3246.
• Difficulty in obtaining regulatory approval for product candidates, with potential for delays, denials, or limited indications.
• Preclinical and early-stage clinical trial results may not be indicative of success in larger trials.
• Clinical trials may be delayed, suspended, or terminated due to safety concerns, regulatory issues, or patient enrollment difficulties.
• Product candidates may cause undesirable side effects, delaying or preventing approval or limiting commercial potential.
• Inability of manufacturers to produce appropriate product volumes may cause development, approval, or commercialization delays.
• Substantial competition in drug discovery, development, and commercialization from companies with greater resources.
• Product candidates may not achieve adequate market acceptance among physicians, patients, and payors.
• Termination or non-contribution of collaboration partners could severely impact development and commercialization.
• Reliance on third-party contractors for clinical trials and manufacturing poses risks of non-performance or termination.
• Shortfalls, delays, or excesses in manufacturing, including supply chain issues and compliance with cGMP.
• Reliance on single-source suppliers for certain product components, risking supply disruption.
• Inadequate protection of proprietary and exclusively licensed technologies, leading to competitive harm.
• Sharing trade secrets with third parties increases risk of discovery or misappropriation by competitors.
• High cost and continuous diligence required to maintain patent protection globally, with risk of invalidation or narrow interpretation.
• Laws in some foreign countries, particularly China, may not protect intellectual property rights to the same extent as the U.S.
• Intellectual property disputes are costly, time-consuming, and may negatively affect competitive position.
• Existence of counterfeit pharmaceutical products, especially in China, could compromise brand and reputation.
• Regulatory approval process is highly uncertain and unpredictable.
• Relationships with customers, physicians, and payors are subject to healthcare fraud and abuse laws, leading to potential penalties for non-compliance.
• Stringent and evolving data privacy and security laws (U.S. and foreign) pose risks of regulatory actions, litigation, and reputational harm.
• Exposure to corruption laws (e.g., FCPA) requires costly compliance programs, with risks of violations and penalties.
• Failure to maintain an effective system of internal control could result in material misstatements and adverse financial impacts.
• Impact of U.S. healthcare reform measures, including drug pricing negotiations and rebates, could adversely affect business model.
• Roxadustat's classification as a Class 2 substance by WADA could limit sales and increase security/distribution costs.
• Employee misconduct or improper activities could result in significant liability or harm reputation.
• Failure to comply with environmental, health, or safety laws could incur fines or penalties.
• Inability to consummate the sale of FibroGen International to AstraZeneca Treasury Limited would severely harm operations and liquidity.
• Risks associated with international operations, including different regulatory requirements, economic weakness, and political instability.
• Highly regulated pharmaceutical industry in China, with regulations subject to change.
• Changes in U.S. and China relations, including tariffs and sanctions, may adversely impact business.
• Risks inherent to operating own manufacturing facility in China, including meeting market demand and regulatory compliance.
• Risk of manufacturing disruption due to geopolitical tensions and U.S. legislation impacting Chinese suppliers (WuXi AppTec, WuXi Biologics, WuXi XDC).
• Difficulties in successfully growing and sustaining roxadustat sales in China due to competition and pricing controls.
• Restrictions on FibroGen Beijing paying dividends or other payments, limiting access to cash from China.
• Currency exchange rate fluctuations and restrictions in China, Japan, and Europe.
• Lack of bank insurance for funds held in China banks.
• Tax inefficiencies associated with offshore corporate structure and changes in tax laws.
• Uncertainties with respect to the China legal system and regulations.
• Changes in China's economic, governmental, or social conditions.
• Potential for additional Chinese requirements, approvals, or permissions in the future.
• Chinese government determining corporate structure does not comply with regulations.
• Exposure to Chinese labor and social insurance laws, with non-compliance risks.
• Potential for impairment of long-lived assets.
• Non-dilutive financing transactions (Morgan Stanley, NovaQuest) could limit cash flow and impose restrictive covenants.
• Loss of senior management and key personnel due to workforce reduction.
• Product liability lawsuits could result in substantial liabilities.
• Computer system failures and cybersecurity incidents could disrupt operations and lead to adverse consequences.
• Third-party service providers exposed to natural disasters and other catastrophes.

Future Outlook

The company anticipates initiating a Phase 2 monotherapy dose optimization study of FG-3246 for mCRPC in the third quarter of 2025, pending the close of the FibroGen International sale. Topline results from the Phase 2 portion of the FG-3246 study in combination with enzalutamide are expected in the fourth quarter of 2025. FibroGen also plans a Phase 3 trial for roxadustat in anemia associated with lower-risk MDS, with FDA alignment on study design. The sale of FibroGen International to AstraZeneca Treasury Limited is expected to close in the third quarter of 2025, providing approximately $210 million in cash. However, the company expects to continue incurring losses and will need substantial additional funding, with substantial doubt about its ability to continue as a going concern if the China sale does not close or if it cannot raise additional capital.

Management Comments

• We anticipate initiation of a Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of mCRPC, along with the exploratory analysis of FG-3180, in the third quarter of 2025, pending close of the sale of FibroGen International to AstraZeneca Treasury Limited.
• We continue to work on our development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndromes (MDS), a high-value indication with significant unmet medical need.
• We had a positive Type-C meeting with the U.S. Food and Drug Administration (FDA) in July 2025 and reached alignment on several elements of our proposed Phase 3 study design for roxadustat in anemia associated with lower-risk MDS.
• We have evaluated measures to access additional cash from our China operations and we believe the sale of FibroGen International represents the most efficient way to access the entirety of our cash from China upon closing of the transaction.
• There is also the potential that we raise additional funds in the U.S. at any time through equity, equity-linked, or debt financing arrangements or from other sources. There can be no assurances that these plans will be successful.
• As a result of these factors, we have determined that there is substantial doubt about our ability to continue as a going concern within 12 months after the date that the financial statements are issued.

Industry Context

The biopharmaceutical industry is highly competitive and capital-intensive, with significant risks associated with drug development, regulatory approvals, and commercialization. FibroGen's focus on novel therapies for cancer and anemia places it in therapeutic areas with high unmet medical needs but also intense competition from larger pharmaceutical companies. The trend of asset divestitures, like FibroGen's China sale, is common for companies seeking to streamline operations, improve liquidity, and focus on core pipeline assets, especially when facing financial pressures or strategic shifts. The increasing scrutiny on drug pricing, particularly in markets like China with volume-based purchasing programs, reflects a broader global trend impacting pharmaceutical revenues. The ongoing challenges with intellectual property enforcement in certain foreign jurisdictions, such as China, also represent a significant industry-wide concern for innovative drug developers.

Comparison to Industry Standards

• FibroGen's significant cost reduction plan, including a 75% U.S. workforce reduction and termination of pamrevlumab programs, is a drastic measure, often seen in biotech companies facing financial distress or clinical trial failures, aiming to extend cash runway and focus on key assets. This is more aggressive than typical cost-cutting seen in stable, profitable large pharma.
• The pending sale of China assets for approximately $210 million is a substantial divestiture, comparable to smaller biotech companies selling off regional rights or non-core assets to larger partners (e.g., AstraZeneca) to shore up liquidity, similar to how smaller biotechs might license out assets to big pharma for upfront payments.
• The 'substantial doubt about going concern' warning is a critical indicator of financial instability, placing FibroGen in a higher risk category compared to most established pharmaceutical companies and even many clinical-stage biotechs that typically have longer cash runways or clearer paths to financing.
• Roxadustat's inclusion in China's volume-based purchasing program and the expected price reduction align with broader trends in major markets where governments exert increasing pressure on drug prices, impacting companies like Innovent Biologics (China) or other global pharma with significant China exposure.
• The development of FG-3246, an ADC for mCRPC, positions FibroGen in a competitive oncology space. Companies like Seagen (now part of Pfizer) and Daiichi Sankyo are leaders in ADC development, and FibroGen's Phase 1/2 data for FG-3246 would be benchmarked against their early-stage ADC pipelines, which often show high response rates in specific patient populations.
• The high effective interest rates on FibroGen's debt (16.13% for term loan, 15.43% for revenue interest financing) are indicative of the higher risk profile perceived by lenders for a company in its financial position, contrasting sharply with the lower borrowing costs available to more financially stable or larger pharmaceutical entities.

Management Changes

Corporate Governance

Legal Proceedings

• A class action lawsuit alleging securities law violations was settled for $28.5 million, fully distributed in Q1 2025 and covered by insurance.
• Seven shareholder derivative complaints asserting similar claims have all been dismissed.
• The company received SEC subpoenas related to roxadustat's cardiovascular safety data and entered into a settlement in May 2025, subject to Commission approval, agreeing to pay a $1.25 million civil penalty.
• Challenges have been filed with the China National Intellectual Property Administration against roxadustat crystal form patents, with revocations upheld on first appeal but remaining on appeal.

Related Party Transactions

• Sales of roxadustat commercial product to Falikang, a distribution entity jointly owned by AstraZeneca and FibroGen Beijing, which is an unconsolidated VIE accounted for as an equity method investment and considered a related party.
• Net product revenue from sales to Falikang were $16.4 million for Q2 2025 and $53.3 million for the six months ended June 30, 2025 (included in discontinued operations).
• Investment income in Falikang was $1.7 million for Q2 2025 and $1.1 million for the six months ended June 30, 2025.
• Accounts receivable, net, from Falikang were $19.1 million as of June 30, 2025 (included in current assets held for sale).

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future capital raises and the impact of the 1-for-25 reverse stock split. The 'going concern' warning poses a substantial risk to investment value. The pending China asset sale could provide a cash infusion, but future revenue streams are uncertain.
• **Employees**: The U.S. workforce was reduced by approximately 75% in Q3 2024, impacting job security and morale. Remaining employees face uncertainty due to the 'going concern' warning.
• **Customers (Astellas, AstraZeneca)**: The termination of the AstraZeneca U.S./RoW agreement and the sale of China assets to AstraZeneca will alter existing collaboration dynamics. Astellas continues to commercialize roxadustat in Europe and Japan, but future revenue from these partnerships is subject to market performance and pricing pressures.
• **Creditors (Morgan Stanley, NovaQuest)**: The company's ability to comply with debt covenants and repay its senior secured term loan facilities (maturing May 2026) and NovaQuest financing depends heavily on the closing of the China asset sale and future financial performance. The 'going concern' warning increases risk for creditors.
• **Regulatory Authorities (FDA, SEC, China SAMR)**: The company is actively engaging with the FDA on clinical trial designs and has settled a legal matter with the SEC, indicating ongoing regulatory scrutiny and compliance efforts. The China SAMR approval is critical for the asset sale.

Next Steps

• Close the sale of FibroGen International to AstraZeneca Treasury Limited in the third quarter of 2025, subject to China SAMR regulatory approval.
• Initiate a Phase 2 monotherapy dose optimization study of FG-3246 for mCRPC in the third quarter of 2025 (pending China sale close).
• Obtain topline results from the Phase 2 portion of the FG-3246 study in combination with enzalutamide in the fourth quarter of 2025.
• Proceed with a planned Phase 3 trial for roxadustat in anemia associated with lower-risk MDS, following alignment with the FDA on study design.
• Manage the impact of roxadustat's inclusion in China's 11th round of volume-based purchasing program, which is expected to lead to further price reductions.
• Repay the senior secured term loan facilities upon the closing of the sale of FibroGen International.
• Evaluate the effects of new FASB accounting guidance (ASU 2024-03 and ASU 2023-09) on related disclosures.
• Monitor trading activities in shares for potential future ownership changes under IRC Section 382.

Key Dates

Recommendation

The company explicitly states 'substantial doubt about its ability to continue as a going concern within 12 months' without the closing of the China asset sale or additional capital. This is a severe red flag for any seasoned investor, indicating significant financial instability and high risk of default or further dilution. While the China asset sale is expected to provide a cash infusion, its closing is subject to regulatory approval and is not guaranteed. The core continuing operations show a significant revenue decline, and future revenue from the key roxadustat product in China is expected to be severely impacted by volume-based purchasing. Despite cost reductions and some pipeline progress, the immediate liquidity concerns and the explicit going concern warning outweigh any potential long-term upside, making it a high-risk investment where capital preservation is paramount.

Keywords

Biopharmaceutical, Oncology, Anemia, Prostate Cancer, Myelodysplastic Syndromes, Roxadustat, EVRENZO, FG-3246, ADC, Antibody-Drug Conjugate, CD46, SEC Filing, 10-Q, Financial Results, Clinical Trials, FDA, AstraZeneca, Astellas, China Market, Going Concern, Cost Reduction, Asset Sale, Intellectual Property, Drug Development, Biotech